

What is claimed is:

1. A method for treating a subject with glaucoma comprising the steps of
5 administering a compound or composition containing an agent, which
antagonize, inhibits, inactivates, reduce, suppresses, antagonizes, and/or limits the
release, synthesis, or production from cells of TNF- α thereby treating the subject
with glaucoma.
- 10 2. The method of claim 1, wherein the compound or composition suppresses the
level or production of TNF- α .
3. The method of claim 1, wherein the molecule is recombinant TNF- α soluble
receptors.
- 15 4. The method of claim 3, wherein the molecule is etanercept.
5. The method of claim 1, wherein the compound or composition inhibits the
production of TNF- α .
- 20 6. The method of claim 1, wherein the compound or composition limits the synthesis
or release of TNF- α from cells.
7. The method of claim 6, wherein the cells are immune cells, lymphocytes, glia and
25 neuron cells.
8. The method of claim 6, wherein the compound is thalidomide.
9. The method of claim 6, wherein the compound or composition is a selective
30 cytokine inhibitor.

10. The method of claim 9, wherein the inhibitor is rolipram or phosphodiesterase 4 inhibitor.
- 3
11. The method of claim 1, wherein the compound or composition inactivates circulating TNF- α .
- 4
12. The method of claim 1, wherein the molecule is anti- TNF- α antibody.
- 5
13. The method of claim 12, wherein the molecule is a monoclonal or polyclonal antibody.
- 6
14. The method of claim 13, wherein the molecule is infliximab.
15. The method of claim 1, wherein the TNF reducer is hydrazine sulfate, pentoxifylline, ketotifen, tenidap, vesnarinone, cyclosporine, peptide T, sulfasalazine, thiorazine, antioxidants, corticosteroids, marijuana, glycyrrhizin, sho-saiko-to, L-carnitine, hyperthermia, or hyperbaric oxygen therapy.
- 7
16. A pharmaceutical composition of claim 1 and a diluent and suitable carrier.
- 8
17. The method of claim 1, wherein the compound or composition is administered ocularly, parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intravascularly, or subcutaneously, intraperitoneal topical drops or ointment, periocular injection, systemically by intravenous injection or orally, intracamerally into the anterior chamber or vitreous, via a depot attached to the intraocular lens implant inserted during surgery, or via a depot placed in the eye sutured in the anterior chamber or vitreous.